SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity ...
Repair Biotechnologies, Inc. ( a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, is pleased to announce that it has ...
SYRACUSE, NEW YORK / ACCESS Newswire / January 21, 2025 / Repair Biotechnologies, Inc. ( a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, ...
Pharmaceutical Technology on MSN15h
Atara’s T cell programmes hit with clinical hold after third-party site woesThe FDA placed a clinical hold on two Atara assets, following an inspection at a third-party site that also led to a CRL for ...
Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications.
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...
3hon MSN
A 14-year-old male has been charged with attempted rape, reckless homicide and several other felonies in connection to an ...
GlobalData on MSN2d
Neuraly and Enigma Biomedical sign deal for PET imaging biomarkerNeuraly and Enigma Biomedical have signed an agreement for PMI04, a positron emission tomography (PET) imaging biomarker for ...
Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development ...
GlobalData on MSN5d
Shionogi awarded $375m from HHS for preventative Covid-19 injectableShionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...
Humacyte (HUMA) announced that it plans to file an Investigational New Drug, IND, application with the U.S. Food and Drug Administration, FDA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback